Tanios S. Bekaii-Saab, MD, discusses safety profile considerations for patients undergoing treatment for hepatocellular carcinoma, and the Oncology Brothers recap the entire discussion.
FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer
Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.
Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis
Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
Survival results were similar among all patients and PD-L1 subgroups with the domvanalimab regimen in gastroesophageal junction adenocarcinoma.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Atebimetinib Plus SOC Chemo Improves Survival/Safety in 1L PDAC
Atebimetinib with gemcitabine and nab-paclitaxel achieved 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.
Alnodesertib Receives FDA Fast Track Designation For ATM– Metastatic CRC